Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers
Amsterdam, the Netherlands and Sydney, Australia 30 September 2024 – Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian pediatric medical research institute, and Omico, an organization uniting over 50 world-class cancer institutes in Australia and New Zealand. The collaboration has […]
